Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
basic toxicokinetics in vivo
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment
Remarks:
no substance purity given, no identification of metabolites, no cannulation of bile-duct

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1981

Materials and methods

Objective of study:
other: absorbtion and excretion
Test guideline
Qualifier:
no guideline followed
Principles of method if other than guideline:
Absorption and excretion of the test substance was investigated quantitatively by radiotracer technique in a GLP study. Additionally the residues of the test substance and its metabolites were determined in blood and in the faeces free body. The radiolabelled substance was applied orally as well as intravenously on male sprague dawley rats. No metabolic identification was done, time-dependent blood plasma-profile were not determined.
GLP compliance:
yes

Test material

Constituent 1
Chemical structure
Reference substance name:
N,N'-hexane-1,6-diylbis[3-(3,5-di-tert-butyl-4-hydroxyphenylpropionamide]
EC Number:
245-442-7
EC Name:
N,N'-hexane-1,6-diylbis[3-(3,5-di-tert-butyl-4-hydroxyphenylpropionamide]
Cas Number:
23128-74-7
Molecular formula:
C40H64N2O4
IUPAC Name:
N,N'-hexane-1,6-diylbis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanamide]
Radiolabelling:
yes
Remarks:
14-C labelled test

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: (han: SPRD/ SPF- albino rats), central institute for test animals, Hannover
- Weight at study initiation: 143.3 , 187.8, 151, 147.5, 188.2 g mean weight per group
- Fasting period before study: the day before application food ration was reduced to half of daily intake (8 g vs. 15 g), thereafter animals got normal daily ration, but the first ration was given 8 hrs after application.
- Housing: individual housing
- Individual metabolism cages: yes
- Diet: normal diet mark Gode (Art. No. 253), Dr. Rupprecht Schott Nachf., Hamburg; 15 g / day
- Water: ad libitum
- Acclimation period: 14 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 1
- Humidity (%): 55 ± 5
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:
other: oral and intravenous
Vehicle:
other: (oral application: olive oil, intravenous application: propanediol-1,3)
Details on exposure:
oral application:
- Concentration in vehicle: 103.2 µg/g and 2179 µg/g solution for doses of 0.28 and 5.4 mg/kg bw, respectively

intravenous application:
- Concentration in vehicle: 383.8 µg/g solution for dose of 0.22 mg/kg bw
Duration and frequency of treatment / exposure:
single exposure, 72 hrs
Doses / concentrationsopen allclose all
Dose / conc.:
5.4 mg/kg bw/day (actual dose received)
Remarks:
test group (14C- labelled test substance); oral application (group I)
Dose / conc.:
0.28 mg/kg bw/day (actual dose received)
Remarks:
test group (14C- labelled test substance), oral application (group II)
Dose / conc.:
0.22 mg/kg bw/day (actual dose received)
Remarks:
test group (14C- labelled test substance); intravenous application (group III)
Dose / conc.:
5.5 mg/kg bw/day (actual dose received)
Remarks:
control group (non-radioactive test substance); oral application (groups 0I und 0II)
Dose / conc.:
0.25 mg/kg bw/day (actual dose received)
Remarks:
control group (non-radioactive test substance); intravenous application (group 0III)
No. of animals per sex per dose / concentration:
4 animals per control group
7 animals per test group
Control animals:
other: male rats administered with non-labelled test substance for oral and intravenous application
Details on dosing and sampling:
PHARMACOKINETIC STUDY (Excretion)
- Tissues and body fluids sampled: urine, faeces, blood, rat bodies bleeded to death and without faeces
- Time and frequency of sampling: (for faeces and urine) 0-6, 6-24, 24- 48, 48- 72 hrs
- Method type(s) for identification: liquid scintilation counter
- Limits of detection: 0.04, 0.8, 0.3, 0.2 ng test substance or metabolites/g sample for urine, faeces, blood and homogenized entire bodies
- other: for determination of the radioactivity in test materials animal materials were mixed and homogenized. Afterwards samples from blood, urine and homogenisates from body were weighed in scintillation measuring glasses. In contrast to this direct taking of samples for faeces probes a lyophilization and pulverization was done. Then test substance was burnt to carbon dioxide and collected in a fixed quantity absorber liquid. After addition of suitable scintillation solution scintillation measurement was done.

Results and discussion

Main ADME resultsopen allclose all
Type:
excretion
Results:
by faeces: 101.6 % (high dose, oral application), 102.7 % (low dose, oral application), 88.7 % (intravenous application) of radioactivity after 72 hrs
Type:
excretion
Results:
by urine: 1.7 % (high dose, oral application), 2.2 % (low dose, oral application), 2.0 % (intravenous application) of radioactivity after 72 hrs
Type:
distribution
Results:
in blood: 0.01 % (high dose, oral application), 0.06 % (low dose, oral application), 0.03 % (intravenous application) of radioactivity after 72 hrs
Type:
distribution
Results:
in whole body (after removal of faeces): 0.35 % (oral application, high dose) of radioactivity after 72 hrs

Toxicokinetic / pharmacokinetic studies

Details on absorption:
By means of the pharmacokinetic results described here no information if substance is absorbed can be given. The test substance could be excreted directly via faeces or excreted via faeces after absorption.
Details on distribution in tissues:
- The residual radioactivities, found after oral and intravenous application of radiolabelled test substance after 72 h in the blood of the rats of test group I, II, and III killed by bleeding to death, were comparatively small and amounted on an average to 0.01, 0.06 and 0.03 % of the applicated radioactivity amounts.
- The residual radioactivities found after oral application of radiolabelled test substance after 72 h in the free of faeces bodies of the killed rats of test group I amounted on an average to 0.35 % of the given radioacitivity amounts.
Details on excretion:
-The radioactivity amounts, orally given to the rats of test group I and II in form of the 14C -labelled test substance, were nearly excreted quantitatively in 72 hrs, favouredly by faeces and only to a smaller extent (on an average up to 1.7 or 2.2 %) on renale way.
- The radioactivity amounts, intravenously given to the rats of test group III in form of radiolabelled test substance were eliminated in 72 hrs on an average to 88.7 % by faeces and to 2.0 % by urine.

- Elimination for intravenous application is considerably slower than via the oral route. Substance is not completely excreted 72 hrs after substance application

Metabolite characterisation studies

Metabolites identified:
not measured

Any other information on results incl. tables

Absorption and elimination of the test substance was investigated quantitatively by radiotracer technique in a GLP study. Additionally the residues of the test substance and its metabolites were determined in blood and in the faeces free body. The radiolabelled substance was applied orally as well as intravenously on male sprague dawley rats (7 per group) with doses of 0.28 and 5.39 mg/kg bw for oral and 0.22 mg/kg bw for intravenous application.

It was shown that the test substance rests only a short time in male rats as well after oral as after intravenous application. After 72 hrs the test substance or its metabolites were nearly quantitatively excreted by faeces. A small share was excreted by the renale way.

By means of the pharmacokinetic results described here no information if substance is absorbed can be given. The test substance could be excreted directly via faeces or excreted via faeces after absorption.

No bioaccumulation potential based on the study results was detected.

Applicant's summary and conclusion

Conclusions:
no bioaccumulation potential based on study results